Navigation Links
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Date:8/8/2013

WOODCLIFF LAKE, N.J., Aug. 8, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell lymphoma (CTCL).  E7777 is designed to have an improved purity profile and manufacturing process. It is currently in a pivotal trial intended to support its submission for approval.

The Orphan Drug Act (ODA) allows FDA to grant orphan status to a drug which has the potential for the treatment, diagnosis, or prevention of a rare disease/disorder that affects fewer than 200,000 people in the United States.

CTCL is a rare type of cancer that begins in the white blood cells and attacks the skin. It is one of several types of lymphoma collectively called non-Hodgkin lymphoma.

Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Media InquiriesInvestor InquiriesLaurie Landau

Alex Scott Eisai Inc.

Eisai Inc.201-746-2510

201-746-2177


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
2. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Agnitio Grants 10,000 New Licenses Globally this Financial Year
4. FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
5. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
6. Cardinal Health Foundation Invites Local Non-profit Organizations To Apply For Grants To Prevent Prescription Drug Abuse
7. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
8. FDA Grants Chimerix Fast Track Designation for CMX001 for the Prevention of Clinically Significant Cytomegalovirus Infection
9. Pancreatic Cancer Action Network Opposes Sequestration Cuts To National Institutes Of Health & Cancer Research Grants
10. State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
11. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Zymo Research Corp., also known as ,The Epigenetics Company, announced ... in a precise manner using the myDNAge ™ test. Based on ... of human genetics and biostatistics at the David Geffen School of ... Zymo Research,s proprietary DNAge ™ technology is used to analyze DNA ... ...
(Date:7/11/2017)... 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a new ... suffer from painful intercourse and other painful pelvic pain conditions such as ... menopause. ... ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void in ...
(Date:7/10/2017)... , July 10, 2017  BDI Group ... and patient support services organization serving specialty pharmacies, ... the launch of four significant, value-added member programs ... insights, better manage reimbursement and improve access and ... factor therapies. ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... “Now Hiring!” is a popular phrase at ... company has achieved record-breaking sales for over 30 consecutive years and now plans to ... The upcoming year offers excitement and growth at HDIS, following the company’s acquisition by ...
(Date:7/25/2017)... ... July 25, 2017 , ... SureVest Insurance ... services to communities across North Carolina, is launching a charity event in conjunction ... support for the ongoing fight against bladder cancer. , The Bladder Cancer Advocacy ...
(Date:7/25/2017)... WI (PRWEB) , ... July 25, 2017 , ... ... Aloria Health, as medical director. Dr. Negrette has more than a decade of ... She has worked closely with individuals fighting addictions, eating disorders, psychotic and manic ...
(Date:7/24/2017)... PARK (PRWEB) , ... July 24, 2017 , ... Engineers ... is bio-compatible, because it produces the same kind of electrical energy that the body ... the form of moving electrons. This flow of electrons out of the battery is ...
(Date:7/24/2017)... ... , ... Cosmetic Town, an online plastic surgery information community, announces a new ... daily basis. , The new video series will feature board-certified doctors explaining the ... , When asked about the new video series, the senior editor of ...
Breaking Medicine News(10 mins):